Show simple item record

Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy

dc.contributor.authorDireskeneli, Haner
dc.contributor.authorOnat, Altan
dc.date.accessioned2021-03-05T18:45:57Z
dc.date.available2021-03-05T18:45:57Z
dc.date.issued2012
dc.identifier.citationOnat A., Direskeneli H., "Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy", CURRENT PHARMACEUTICAL DESIGN, cilt.18, ss.1465-1477, 2012
dc.identifier.issn1381-6128
dc.identifier.othervv_1032021
dc.identifier.otherav_cbe79819-8846-410f-84a6-57fe24c76711
dc.identifier.urihttp://hdl.handle.net/20.500.12627/135031
dc.description.abstractThe article reviews the evidence and extent of the excess cardiovascular risk in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis. RA entails nearly twice as high a standardized mortality ratio and is considered an equivalent of type 2 diabetes with regard to cardiovascular risk. The associated excess cardiovascular risk can only partly be explained by traditional risk factors, and the underlying inflammation is crucially involved in the pathogenesis.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleExcess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
dc.typeMakale
dc.relation.journalCURRENT PHARMACEUTICAL DESIGN
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume18
dc.identifier.issue11
dc.identifier.startpage1465
dc.identifier.endpage1477
dc.contributor.firstauthorID204001


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record